HOME >> BIOLOGY >> NEWS
Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity

A new study sheds light on how some small-molecule tyrosine kinase inhibitors, including two that are currently being used clinically to treat cancer, interact with wild-type and mutated forms of the epidermal growth factor receptor (EGFR). The research, published in the March issue of the journal Cancer Cell, published by Cell Press, may help to guide rational use of currently available EGFR inhibitors and provides new direction for the design and development of even more potent inhibitors that are tailored to specific EGFR mutants.

Many human malignancies exhibit mutated forms of the EGFR, a tyrosine kinase that plays a critical role in signaling pathways controlling cell proliferation and survival. Although the specific mechanisms are unclear, studies have shown that some EGFR mutations are associated with increased sensitivity to small-molecule tyrosine kinase inhibitors. To better understand how distinct mutant EGFRs interact with inhibitors on a structural level, Dr. Michael J. Eck from Harvard Medical School and the Dana-Farber Cancer Institute and colleagues studied the enzyme activity of two lung cancer-derived EGFR mutants and determined their crystal structures when bound to several different commonly used inhibitors.

The researchers found that the L858R and G719S EGFR mutants disrupt inhibitory interactions within the EGFR, leading to a characteristic overactivation of the enzyme. Structural examination of the inhibitor complexes, which included the drug gefitinib (Iressa), revealed that the mutations can affect the way the inhibitors interact with the enzyme. Interestingly, the inhibitors gefitinib and AEE788 bind much more tightly to the L858R mutant than to the wild-type EGFR. This finding explains the observation that tumors bearing this mutation have been found to be more responsive to treatment with gefitinib.

The researchers conclude that mutations of the EGFR dramatically influence inhibitor binding and suggest th
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
12-Mar-2007


Page: 1 2

Related biology news :

1. When two mutants collide: How XPD disorders can be partially rescued in compound heterozygotes
2. WPI professor to represent American Mathematical Society at exhibition on science funding
3. Widely used iron nanoparticles exhibit toxic effects on neuronal cells
4. Explore frontiers of science at June 7 congressional exhibition
5. Art of Science exhibit opens at Princeton
6. Robot exhibition to highlight WTEC international study of robotics
7. Gladstone Institutes assists with Exploratorium stem cell exhibit
8. The wonders of science on display at June 21 congressional exhibition
9. Institute for OneWorld Health to exhibit at BIO
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. Sugar and spice and everything nice: Health differences in newborn girls and boys

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... , ... July 20, 2017 , ... ... seminar on digital pathology and artificial intelligence Tuesday, July 25, during the Association ... Baras from Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial ... trial sites and study participants truly unified. TrialKit, a native mobile app, empowers ... Part 11) research studies entirely on mobile devices. With TrialKit, clinical researchers can ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading ... science and technology company, has implemented Genedata Biologics ™ to scale-up their ... Oncology, Immunology, and Neurodegenerative Diseases. , The need to systematically evaluate large panels ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope ... released the first phase of the Allotrope Framework for commercial use. , The ... created to “not only elevate the critical role of information technology in modern ...
Breaking Biology Technology:
Cached News: